China Pharmaceuticals, Inc. Effects 1 For 3 Reverse Share Split

China Pharmaceuticals, Inc. (CFMID 0.00, 0.00, 0.00%) ("China Pharmaceuticals, Inc." or the "Company"), one of China's leading manufacturers and distributors of prescription and over-the-counter pharmaceuticals, today announced that it has effected a 1 for 3 reverse share split as of September 22, 2010.China Pharmaceuticals, Inc. has officially filed amendments to its articles to the state of Nevada to affect a 1 for 3 reverse share split. The company had also filed notice of same to FINRA. The objective of the reverse share split is to better position the company for a senior stock exchange listing. "Today's announcement further demonstrates to our shareholders that we are taking steps that we feel are necessary to position the company to attain a senior stock exchange listing," stated Mr. Guozhu Wang, Chairman and Chief Executive Officer of China Pharmaceuticals, Inc. In conjunction with the reverse split, a temporary "D" has been added to the end of the Company's existing trading symbol (CFMID). Typically, the "D" is automatically removed 20 days after the share split becomes effective.About China Pharmaceuticals, Inc.China Pharmaceuticals, Inc. www.chinapharmaceuticalsinc.com has its headquarters based in the industrial city of Xi'an, Shaanxi Province, China. The Company identifies, discovers, develops, manufactures and distributes both prescription and over-the counter pharmaceutical products, including both conventional and traditional Chinese medicines, for the treatment of some of the most common ailments and diseases. China Pharmaceuticals, Inc. currently manufactures 132 pharmaceutical products in 11 dosage forms, including capsules, oral solutions, tablets, granules, syrups, medicinal teas, tinctures and solutions for injection. The Company currently markets and distributes 111 prescription drugs representing 78% of sales distributed via 56 sales offices (including two company-owned distribution and logistics centers) to a network of hospitals and clinics nationwide. China Pharmaceuticals, Inc. operates two modern high-tech manufacturing facilities based in Hanzhong and the Xi'an Jinghe Industrial Zone, in Shaanxi Province.